Morgan Stanley initiated coverage on three AI-integrated biotechnology firms, Absci, Schrodinger (NASDAQ:SDGR), and Recursion Pharmaceuticals, flagging divergent business models and upcoming catalysts ...

Special edition Stanley tumblers are selling out, but these are still in stockREAD THE FULL STORY:Ready for some fireworks? Find out when and where you can see the showCHECK OUT WAPT:Get the latest ...

Morgan Stanley (NYSE:MS) has begun coverage of Genmab (CSE:GMAB) (NASDAQ:GMAB) with an Equal-Weight rating and a price objective of $24, reduced slightly from the previous $25 target.